Targeting MYCN in Neuroblastoma by BET Bromodomain Inhibition

Bromodomain inhibition comprises a promising therapeutic strategy in cancer, particularly for hematologic malignancies. To date, however, genomic biomarkers to direct clinical translation have been lacking. We conducted a cell-based screen of genetically-defined cancer cell lines using a prototypica...

Description complète

Enregistré dans:
Détails bibliographiques
Auteurs principaux: Puissant, Alexandre, Frumm, Stacey M., Alexe, Gabriela, Bassil, Christopher F., Qi, Jun, Chanthery, Yvan H., Nekritz, Erin A., Zeid, Rhamy, Gustafson, W. Clay, Greninger, Patricia, Garnett, Matthew J., McDermott, Ultan, Benes, Cyril H., Kung, Andrew L., Weiss, William A., Bradner, James E., Stegmaier, Kimberly
Format: Artigo
Langue:Inglês
Publié: 2013
Sujets:
Article
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC3672953/
https://ncbi.nlm.nih.gov/pubmed/23430699
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/2159-8290.CD-12-0418
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires